{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:37:09Z","timestamp":1769099829139,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271373"],"award-info":[{"award-number":["82271373"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7232075"],"award-info":[{"award-number":["7232075"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00415-024-12494-y","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T05:01:46Z","timestamp":1718168506000},"page":"5326-5332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review"],"prefix":"10.1007","volume":"271","author":[{"given":"Hansong","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuetong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2275-5039","authenticated-orcid":false,"given":"Hongyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"12494_CR1","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"GBD","year":"2017","unstructured":"GBD (2017) Causes of Death Collaborators (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1736\u20131788. https:\/\/doi.org\/10.1016\/S0140-6736(18)32203-7","journal-title":"Lancet"},{"key":"12494_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"12494_CR3","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","volume":"20","author":"AB Benson","year":"2022","unstructured":"Benson AB, Venook AP, Al-Hawary MM et al (2022) Rectal Cancer, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:1139\u20131167. https:\/\/doi.org\/10.6004\/jnccn.2022.0051","journal-title":"J Natl Compr Canc Netw"},{"key":"12494_CR4","doi-asserted-by":"publisher","first-page":"806","DOI":"10.6004\/jnccn.2020.0032","volume":"18","author":"AB Benson","year":"2020","unstructured":"Benson AB, Venook AP, Al-Hawary MM et al (2020) NCCN guidelines insights: rectal cancer, version 6.2020. J Natl Compr Canc Netw 18:806\u2013815. https:\/\/doi.org\/10.6004\/jnccn.2020.0032","journal-title":"J Natl Compr Canc Netw"},{"key":"12494_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM et al (2021) Colon Cancer, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19:329\u2013359. https:\/\/doi.org\/10.6004\/jnccn.2021.0012","journal-title":"J Natl Compr Canc Netw"},{"key":"12494_CR6","doi-asserted-by":"publisher","first-page":"1032314","DOI":"10.3389\/fimmu.2022.1032314","volume":"13","author":"W Hou","year":"2022","unstructured":"Hou W, Yi C, Zhu H (2022) Predictive biomarkers of colon cancer immunotherapy: Present and future. Front Immunol 13:1032314. https:\/\/doi.org\/10.3389\/fimmu.2022.1032314","journal-title":"Front Immunol"},{"key":"12494_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/bjs\/znab342","volume":"108","author":"A Kanani","year":"2021","unstructured":"Kanani A, Veen T, S\u00f8reide K (2021) Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. Br J Surg 108:1417\u20131425. https:\/\/doi.org\/10.1093\/bjs\/znab342","journal-title":"Br J Surg"},{"key":"12494_CR8","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C, Chen Y-P, Du X-J et al (2018) Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363:k4226. https:\/\/doi.org\/10.1136\/bmj.k4226","journal-title":"BMJ"},{"key":"12494_CR9","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN et al (2017) Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies. JAMA Neurol 74:1216\u20131222. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"key":"12494_CR10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","volume":"22","author":"X Zhou","year":"2021","unstructured":"Zhou X, Yao Z, Bai H et al (2021) Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol 22:1265\u20131274. https:\/\/doi.org\/10.1016\/S1470-2045(21)00333-8","journal-title":"Lancet Oncol"},{"key":"12494_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"12494_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin 70:86\u2013104. https:\/\/doi.org\/10.3322\/caac.21596","journal-title":"CA Cancer J Clin"},{"key":"12494_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/bs.acr.2019.03.003","volume":"143","author":"RE O\u2019Neill","year":"2019","unstructured":"O\u2019Neill RE, Cao X (2019) Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. Adv Cancer Res 143:145\u2013194. https:\/\/doi.org\/10.1016\/bs.acr.2019.03.003","journal-title":"Adv Cancer Res"},{"key":"12494_CR14","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang Q, Chen Y, Li X et al (2022) The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol 13:964442. https:\/\/doi.org\/10.3389\/fimmu.2022.964442","journal-title":"Front Immunol"},{"key":"12494_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"key":"12494_CR16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5732\/cjc.014.10122","volume":"33","author":"E Sharon","year":"2014","unstructured":"Sharon E, Streicher H, Goncalves P, Chen HX (2014) Immune checkpoint inhibitors in clinical trials. Chin J Cancer 33:434\u2013444. https:\/\/doi.org\/10.5732\/cjc.014.10122","journal-title":"Chin J Cancer"},{"key":"12494_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"12494_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 168:121\u2013130. https:\/\/doi.org\/10.7326\/M17-2073","journal-title":"Ann Intern Med"},{"key":"12494_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","volume":"137","author":"A Fellner","year":"2018","unstructured":"Fellner A, Makranz C, Lotem M et al (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol 137:601\u2013609. https:\/\/doi.org\/10.1007\/s11060-018-2752-5","journal-title":"J Neurooncol"},{"key":"12494_CR20","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2174\/1570159X19666201230151224","volume":"19","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Zhang C, Zhou L et al (2021) Immune checkpoint inhibitors and neurotoxicity. Curr Neuropharmacol 19:1246\u20131263. https:\/\/doi.org\/10.2174\/1570159X19666201230151224","journal-title":"Curr Neuropharmacol"},{"key":"12494_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG (2017) Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 82:128\u2013136. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.041","journal-title":"Eur J Cancer"},{"key":"12494_CR22","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"12494_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","volume":"106","author":"A Moreira","year":"2019","unstructured":"Moreira A, Loquai C, Pf\u00f6hler C et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12\u201323. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.033","journal-title":"Eur J Cancer"},{"key":"12494_CR24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","volume":"11","author":"Y-T Huang","year":"2020","unstructured":"Huang Y-T, Chen Y-P, Lin W-C et al (2020) Immune Checkpoint Inhibitor-Induced Myasthenia Gravis. Front Neurol 11:634. https:\/\/doi.org\/10.3389\/fneur.2020.00634","journal-title":"Front Neurol"},{"key":"12494_CR25","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E et al (2021) Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist 26:1052\u20131061. https:\/\/doi.org\/10.1002\/onco.13931","journal-title":"Oncologist"},{"key":"12494_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2217\/imt-2017-0043","volume":"9","author":"Y Hasegawa","year":"2017","unstructured":"Hasegawa Y, Kawai S, Ota T et al (2017) Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review. Immunotherapy 9:701\u2013707. https:\/\/doi.org\/10.2217\/imt-2017-0043","journal-title":"Immunotherapy"},{"key":"12494_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10637-023-01347-6","volume":"41","author":"C Wang","year":"2023","unstructured":"Wang C, Zeng H, Fang W, Song L (2023) Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis. Invest New Drugs 41:333\u2013339. https:\/\/doi.org\/10.1007\/s10637-023-01347-6","journal-title":"Invest New Drugs"},{"key":"12494_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/CJI.0000000000000161","volume":"40","author":"E Chang","year":"2017","unstructured":"Chang E, Sabichi AL, Sada YH (2017) Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder. J Immunother 40:114\u2013116. https:\/\/doi.org\/10.1097\/CJI.0000000000000161","journal-title":"J Immunother"},{"key":"12494_CR29","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","volume":"92","author":"A Johansen","year":"2019","unstructured":"Johansen A, Christensen SJ, Scheie D et al (2019) Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology 92:663\u2013674. https:\/\/doi.org\/10.1212\/WNL.0000000000007235","journal-title":"Neurology"},{"key":"12494_CR30","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.3390\/ijms21093054","volume":"21","author":"AG Solimando","year":"2020","unstructured":"Solimando AG, Crudele L, Leone P et al (2020) Immune checkpoint inhibitor-related myositis: from biology to bedside. Int J Mol Sci 21:3054. https:\/\/doi.org\/10.3390\/ijms21093054","journal-title":"Int J Mol Sci"},{"key":"12494_CR31","doi-asserted-by":"publisher","first-page":"1001444","DOI":"10.3389\/fimmu.2022.1001444","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang Z, Wu G, Zhang X et al (2022) Current progress and future perspectives of neoadjuvant anti-PD-1\/PD-L1 therapy for colorectal cancer. Front Immunol 13:1001444. https:\/\/doi.org\/10.3389\/fimmu.2022.1001444","journal-title":"Front Immunol"},{"key":"12494_CR32","doi-asserted-by":"publisher","first-page":"682262","DOI":"10.3389\/fimmu.2021.682262","volume":"12","author":"S Liang","year":"2021","unstructured":"Liang S, Yang J, Lin Y et al (2021) Immune myocarditis overlapping with myasthenia gravis due to Anti-PD-1 treatment for a chordoma patient: a case report and literature review. Front Immunol 12:682262. https:\/\/doi.org\/10.3389\/fimmu.2021.682262","journal-title":"Front Immunol"},{"key":"12494_CR33","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"12494_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA et al (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7:319. https:\/\/doi.org\/10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"12494_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475\u2013490. https:\/\/doi.org\/10.1016\/S1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"key":"12494_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","volume":"20","author":"DJ Irvine","year":"2020","unstructured":"Irvine DJ, Dane EL (2020) Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol 20:321\u2013334. https:\/\/doi.org\/10.1038\/s41577-019-0269-6","journal-title":"Nat Rev Immunol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12494-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12494-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12494-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T15:17:30Z","timestamp":1723475850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12494-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["12494"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12494-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"11 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The relative of the patient has consented to the submission of the case report to the journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}